Decision Resources Group to Present One-Day Biologics and Biosimilars Seminar in New York City on October 4

Decision Resources Group to Present One-Day Biologics and Biosimilars Seminar in New York City on October 4

Decision Resources Group

[email protected]

Decision Resources Group will bring the latest installment of its well-regarded to New York City this fall. will be held on October 4, 2012. This high-value, one-day seminar has been developed specifically for biopharmaceutical market research executives as well as biologics and biosimilars product teams. Expert analysts from Decision Resources Group companies—Decision Resources and BioTrends Research Group—will share their latest research findings on key biologics and biosimilars trends.

Presentation topics include:

For more information on the topics that will be discussed, please visit:

Members of the media covering the biopharmaceutical industry are invited to attend.

Thursday, October 4, 2012. Registration opens at 8:00 a.m.; presentations begin at 9:00 a.m.

New York, N.Y.

The seminar will be hosted byDecision Resources Group, one of the world’s leading research and advisory firms focusing on healthcare insights and analysis. Presentation content will be derived from products from Decision Resources and BioTrends Research Group.

Media interested in attending the seminar should contact Lisa Osgood at or 781-993-2606 for additional information.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.